US2022133685A1PendingUtilityA1
Fast-acting plant-based medicinal compounds and nutritional supplements
Est. expiryDec 2, 2036(~10.4 yrs left)· nominal 20-yr term from priority
A61K 36/3482A61K 31/658A61K 2236/333A61P 29/02A61P 25/04A61K 47/22A61K 33/06A61K 33/02A61K 31/353A61K 9/4858A61K 9/2013A61K 45/06A61K 31/20A61K 9/4891A61K 9/4808A61K 9/08A61K 47/18A61K 9/0095A61K 36/00A61K 9/20A61P 25/00A61K 9/0058A61K 9/0053A61K 9/10A61K 33/00A61K 31/05A61K 31/352A61K 36/185A61K 31/192
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A fast-acting plant-based composition formulated for oral delivery comprising (i) THC and/or CBD and (ii) N-[8-(2-hydroxybenzoyl) amino] caprylate.
2 . The fast-acting plant-based composition of claim 1 , wherein the N-[8-(2-hydroxybenzoyl) amino] caprylate provides an administration benefit.
3 . The fast-acting plant-based composition of claim 2 , wherein the administration benefit is a dose-dependent administration benefit.
4 . The fast-acting plant-based composition of claim 3 , wherein the dose-dependent administration benefit is at a dose concentration of 1-500 mg/mL N-[8-(2-hydroxybenzoyl) amino] caprylate.
5 . The fast-acting plant-based composition of claim 3 , wherein the dose-dependent administration benefit of the N-[8-(2-hydroxybenzoyl) amino] caprylate is at a dose one to one hundred times the dose of the THC and/or CBD.
6 . A fast-acting plant-based composition formulated for oral delivery comprising (i) vegetable matter with an aqueous solubility of less than 0.1 mg/ml and (ii) N-[8-(2-hydroxybenzoyl) amino] caprylate.
7 . A fast-acting plant-based composition formulated for oral delivery comprising (i) THC and/or CBD and (ii) N-[8-(2-hydroxybenzoyl) amino] caprylic acid.
8 . The fast-acting plant-based composition of claim 7 , wherein the N-[8-(2-hydroxybenzoyl) amino] caprylic acid provides an administration benefit.
9 . The fast-acting plant-based composition of claim 8 , wherein the administration benefit is a dose-dependent administration benefit.
10 . The fast-acting plant-based composition of claim 9 , wherein the dose-dependent administration benefit is at a dose concentration of 1-500 mg/mL N-[8-(2-hydroxybenzoyl) amino] caprylic acid.
11 . The fast-acting plant-based composition of claim 9 , wherein the dose-dependent administration benefit of the N-[8-(2-hydroxybenzoyl) amino] caprylic acid is at a dose one to one hundred times the dose of the THC and/or CBD.
12 . A fast-acting plant-based composition formulated for oral delivery comprising (i) vegetable matter with an aqueous solubility of less than 0.1 mg/ml and (ii) N-[8-(2-hydroxybenzoyl) amino] caprylic acid.
13 . A plant-based composition comprising vegetable matter and an N-acylated fatty amino acid or a salt thereof.
14 . A plant-based composition comprising a botanical product and an N-acylated fatty amino acid or a salt thereof.
15 . A plant-based composition of claim 13 wherein the vegetable matter is derived from Calophyllum brasiliense, Calophyllum caledonicurn, Calophyllum inophyllum, Calophyllum soulattri, Uncaria tomentosa, Thymus vulgaris, Matricaria recutita, Salix alba, Calendula officinalis, Usnea barbata, Ligusticum porterii-osha, Gaultheria procumbens, Camellia sinensis, Vaccinium myrtillus, Melissa officinalis, Allium sativum, Camellia sinensis, Krameria triandra, Punica granatum, Viburnum plicatum, Nicotiana tabacum, Duboisia hopwoodii, Asclepias syriaca, Curcuma longa, Cannabis sativa, Cannabis indica, Cannabis ruderalis and/or Acer spp, or an extract thereof.
16 . A plant-based composition of claim 13 wherein the vegetable matter is derived from cannabis.
17 . A plant-based composition of claim 13 wherein the vegetable matter is derived from Cannabis sativa, Cannabis ruderalis , or Cannabis indica.
18 . A plant-based composition of claim 13 comprising a cannabis extract.
19 . A plant-based composition of claim 13 comprising cannabinoids.
20 . A plant-based composition of claim 13 comprising Δ9-Tetrahydrocannabinol (THC) and cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA) and/or mixtures thereof.
21 . A plant-based composition of claim 13 comprising flavonoid compounds, terpenes, or terpenoids.
22 . A plant-based composition of claim 13 wherein the N-acylated fatty amino acid comprises one or more of Compounds I-XXXV ( FIG. 3 ), or Compounds a-r ( FIG. 4 ).
23 . A plant-based composition of claim 13 wherein the N-acylated fatty amino acid comprises monosodium-N-salicyloyl-8-aminocaprylate, disodium-N-salicyloyl-8-aminocaprylate, or N-(salicyloyl)-8-aminocaprylic acid.
24 . A plant-based composition of claim 13 wherein the N-acylated fatty amino acid or a salt thereof comprises
wherein X and Z are independently H, a monovalent cation, a divalent metal cation, or an organic cation.
25 . The plant-based composition of claim 24 , wherein the monovalent cation is sodium or potassium.
26 . The plant-based composition of claim 24 , wherein the metal cation is calcium or magnesium.
27 . The plant-based composition of claim 24 , wherein the organic cation is ammonium or tetramethylammonium.
28 . The plant-based composition of claim 24 , wherein X is H.
29 . The plant-based composition of claim 24 , wherein X is a monovalent cation comprising sodium or potassium.
30 . The plant-based composition of claim 24 , wherein X is a divalent metal cation comprising calcium or magnesium.
31 . The plant-based composition of claim 24 , wherein X is an organic cation comprising ammonium or tetramethylammonium.
32 . The plant-based composition of claim 24 , wherein Z is H.
33 . The plant-based composition of claim 24 wherein Z is a monovalent cation comprising sodium or potassium.
34 . The plant-based composition of claim 24 wherein Z is a divalent cation comprising calcium or magnesium.
35 . The plant-based composition of claim 24 , wherein X is H and Z is H.
36 . The plant-based composition of claim 24 , wherein X is H and Z is sodium.
37 . The plant-based composition of claim 24 , wherein X is sodium and Z is sodium.
38 . A plant-based composition of claim 13 wherein the N-acylated fatty amino acid or salt thereof provides an administration benefit.
39 . A plant-based composition of claim 38 wherein the administration benefit is a dose-dependent administration benefit.
40 . A plant-based composition of claim 39 wherein the dose-dependent administration benefit is at a dose of 100-200 mg.
41 . The plant-based composition of claim 39 , wherein the dose-dependent administration benefit is at a dose concentration of 1-500 mg/mL N-acylated fatty amino acid or salt thereof.
42 . The plant-based composition of claim 39 , wherein the dose-dependent administration benefit of the N-acylated fatty amino acid or salt thereof is at a dose of one to one hundred times the dose of the vegetable matter.
43 . An plant-based composition of claim 38 wherein the administration benefit comprises one or more of increased absorption of a measured component of vegetable matter, increased bioavailability of a measured component of vegetable matter, faster onset of action of a measured component of vegetable matter, higher peak concentrations of a measured component of vegetable matter, faster time to peak concentrations of a measured component of vegetable matter, increased subjective therapeutic efficacy, increased objective therapeutic efficacy, improved taste, and improved mouthfeel as compared to a control composition without the N-acylated fatty amino acid.
44 . A plant-based composition of claim 13 wherein the plant-based composition is a medicinal composition.
45 . A plant-based composition of claim 13 wherein the plant-based composition is a nutritional supplement.
46 . A plant-based composition of claim 13 comprising a botanical product.
47 . A plant-based composition of claim 13 comprising a surfactant, detergent, azone, pyrrolidone, glycol or bile salt.
48 . A plant-based composition of claim 13 comprising a therapeutically effective amount of vegetable matter.
49 . The plant-based composition of claim 48 , wherein the therapeutically effective amount of vegetable matter is at a dose concentration of 1 mg/mL to 50 mg/mL.
50 . The plant-based composition of claim 48 , wherein the therapeutically effective amount of vegetable matter is at a dose of one to one hundred times less than the dose of the N-acylated fatty amino acid or salt thereof.
51 . A plant-based composition of claim 48 wherein the therapeutically effective amount treats a symptom of acquired hypothyroidism, acute gastritis, addiction, ADHD, agoraphobia, AIDS, AIDS-related anorexia, alcoholism, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ankyloses, anxiety, arthritis, Asperger's syndrome, asthma, atherosclerosis, autism, auto-immune diseases, bacterial infections, bipolar disorder, bone loss, blood disorders, brain injury/stroke, cachexia, cancer, carpal tunnel syndrome, cerebral palsy, cervical disk disease, cervicobrachial syndrome, chronic fatigue syndrome, chronic pain, cluster headache, conjunctivitis, Crohn's disease, cystic fibrosis, depression, dermatitis, diabetes, dystonia, eating disorders, eczema, epilepsy, fever, fibromyalgia, flu, fungal infection, gastrointestinal disorders, glaucoma, glioma, Grave's disease, heart disease hepatitis, herpes, Huntington's disease, hypertension, impotence, incontinence, infant mortality, inflammation, inflammatory bowel disease (IBD), insomnia, liver fibrosis, mad cow disease, menopause, metabolic disorders, migraine headaches, motion sickness, MRSA, multiple sclerosis (MS), muscular dystrophy, mucosal lesions, nail patella syndrome, nausea and vomiting associated with cancer chemotherapy, neuroinflammation, nicotine addiction, obesity, obsessive compulsive disorder (OCD), pain, pancreatitis, panic disorder, Parkinson's disease, periodontal disease, peripheral neuropathy, phantom limb pain, poison ivy allergy, premenstrual syndrome (PMS), proximal myotonic myopathy, post-traumatic stress disorder (PTSD), psoriasis, Raynaud's disease, restless leg syndrome, schizophrenia, scleroderma, septic shock, shingles herpes zoster), sickle cell disease, seizures, sleep apnea, sleep disorders, spinal injuries, stress, stuttering, temporomandibular joint disorder (TMJ), tension headaches, tinnitus, Tourette's syndrome, traumatic memories, wasting syndrome, and withdrawal.
52 . A plant-based composition of claim 13 comprising vitamins or minerals.
53 . A plant-based composition of claim 13 comprising vitamins and minerals.
54 . A plant-based composition of claim 52 or 53 wherein the vitamins are selected from one or more of Vitamin A, Vitamin B1, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, or Vitamin K.
55 . A plant-based composition of claim 52 or 53 wherein the minerals are selected from one or more of calcium, chromium, iodine, iron, magnesium, selenium and/or zinc.
56 . An oral formulation comprising a plant-based composition of claim 13 .
57 . An oral formulation of claim 56 wherein the oral formulation is swallowable or chewable.
58 . An oral formulation of claim 56 wherein the oral formulation is liquid or solid.
59 . An oral formulation of claim 56 wherein the oral formulation is a solution, suspension, or spray.
60 . An oral formulation of claim 56 wherein the oral formulation is a tablet, capsule or sachet.
61 . An oral formulation of claim 56 wherein the oral formulation is flavored.
62 . A method of preparing an oral formulation of cannabis having a faster onset of action, wherein the method comprises adding an absorption enhancer to the oral formulation of cannabis and wherein the oral formulation of cannabis has a faster onset of action than an oral formulation of cannabis without an absorption enhancer.
63 . The method of claim 62 , wherein the absorption enhancer is an N-acylated fatty amino acid or a salt thereof.
64 . The method of claim 62 , wherein the N-acylated fatty amino acid or a salt thereof comprises
wherein X and Z are independently H, a monovalent cation, a divalent metal cation, or an organic cation.
65 . The method of claim 62 , wherein the N-acylated fatty amino acid is selected from monosodium-N-salicyloyl-8-aminocaprylate, disodium-N-salicyloyl-8-aminocaprylate, and N-(salicyloyl)-8-aminocaprylic acid.
66 . The method of claim 62 , wherein the absorption enhancer is in an amount one to one-hundred times the amount of cannabis.
67 . A method of treating a subject in need thereof including administering a therapeutically effective amount of a composition of claim 13 to the subject thereby treating the subject in need thereof.
68 . A method of claim 67 wherein the therapeutically effective amount provides an effective amount, a prophylactic treatment, and/or a therapeutic treatment.
69 . The method of claim 67 , wherein the therapeutically effective amount of the composition comprises the N-acylated fatty amino acid or salt thereof at a dose one to one hundred times the dose of the vegetable matter.
70 . A method of reducing or eliminating one or more symptoms of a disease or disorder in a human subject,
wherein said method includes delivering a therapeutically effective amount of a composition of claim 13 to the subject, thereby reducing or eliminating one or more symptoms of the disease or disorder, and wherein said disease or disorder is acquired hypothyroidism, acute gastritis, addiction, ADHD, agoraphobia, AIDS, AIDS-related anorexia, alcoholism, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ankyloses, anxiety, arthritis, Asperger's syndrome, asthma, atherosclerosis, autism, auto-immune diseases, bacterial infections, bipolar disorder, bone loss, blood disorders, brain injury/stroke, cachexia, cancer, carpal tunnel syndrome, cerebral palsy, cervical disk disease, cervicobrachial syndrome, chronic fatigue syndrome, chronic pain, cluster headache, conjunctivitis, Crohn's disease, cystic fibrosis, depression, dermatitis, diabetes, dystonia, eating disorders, eczema, epilepsy, fever, fibromyalgia, flu, fungal infection, gastrointestinal disorders, glaucoma, glioma, Grave's disease, heart disease hepatitis, herpes, Huntington's disease, hypertension, impotence, incontinence, infant mortality, inflammation, inflammatory bowel disease (IBD), insomnia, liver fibrosis, mad cow disease, menopause, metabolic disorders, migraine headaches, motion sickness, MRSA, multiple sclerosis (MS), muscular dystrophy, mucosal lesions, nail patella syndrome, nausea and vomiting associated with cancer chemotherapy, neuroinflammation, nicotine addiction, obesity, obsessive compulsive disorder (OCD), osteoporosis, osteopenia, pain, pancreatitis, panic disorder, Parkinson's disease, periodontal disease, peripheral neuropathy, phantom limb pain, poison ivy allergy, premenstrual syndrome (PMS), proximal myotonic myopathy, post-traumatic stress disorder (PTSD), psoriasis, Raynaud's disease, restless leg syndrome, schizophrenia, scleroderma, septic shock, shingles herpes zoster), sickle cell disease, seizures, sleep apnea, sleep disorders, spinal injuries, stress, stuttering, temporomandibular joint disorder (TMJ), tension headaches, tinnitus, Tourette's syndrome, traumatic memories, wasting syndrome, or withdrawal syndrome.
71 . The method of claim 70 , wherein the therapeutically effective amount of the composition comprises the N-acylated fatty amino acid or salt thereof at a dose one to one hundred times the dose of the vegetable matter.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.